{"id":"W2985333121","doi":"10.1093/eurheartj/ehz809","title":"Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"Esperion Therapeutics; Idorsia Pharmaceuticals; Daiichi Sankyo Europe; Servier; Belvoir Media Group; Medicines Company; Regado Biosciences; Novo Nordisk; Daiichi-Sankyo; AstraZeneca; Amarin Corporation; Luitpold Pharmaceuticals; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Amgen; Pfizer; Bayer HealthCare; Sanofi; American Heart Association","keywords":"Medicine; Alirocumab; Internal medicine; Acute coronary syndrome; Cardiology; Intensive care medicine; Myocardial infarction; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005760915,0.0004322135,0.002533983,0.0007271677,0.0001450497,0.0001016498,0.0002740711,0.00008621773,0.0002352483],"category_scores_gemma":[0.000210048,0.0002900362,0.004250893,0.0005983984,0.00003751686,0.0002174505,0.0001299745,0.000665452,0.0004059905],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001432127,"about_ca_system_score_gemma":0.00009350022,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004286832,"about_ca_topic_score_gemma":0.000002468057,"domain_scores_codex":[0.9942872,0.002106655,0.0007637478,0.0005634176,0.001706635,0.0005723345],"domain_scores_gemma":[0.997187,0.0001566254,0.0001700588,0.001679958,0.0001278837,0.0006784854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01585615,0.0002282456,0.9346656,0.0001571822,0.02499511,0.004290541,0.0002526463,0.0004417193,0.0002102163,0.000003843799,0.0002038288,0.01869498],"study_design_scores_gemma":[0.02620709,0.007635334,0.9533305,0.0001582904,0.006825884,0.001035306,0.00007208166,0.00001015338,0.0002008759,0.00000136191,0.004199209,0.0003239156],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958008,0.0005186821,0.0001437609,0.0003210985,0.0008735919,0.001432851,0.00001383685,0.00006164471,0.0008337693],"genre_scores_gemma":[0.9971943,0.00006894892,0.0004662631,0.00091987,0.000511569,0.00001758736,0.00001569852,0.0001035515,0.0007022135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01866496,"threshold_uncertainty_score":0.9999552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02351587982491802,"score_gpt":0.3218050398897973,"score_spread":0.2982891600648792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}